Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

CellPro/Corange $30 mil. compromise returns CEPRATE marketing rights under proposed agreement.

Executive Summary

CORANGE/CELLPRO MODIFIED AGREEMENT TO FOCUS ON GENE THERAPY, CellPro announced May 1. Proposed terms provide for a $30 mil. payment to CellPro in exchange for 1 mil. newly issued shares of CellPro common stock and a non-exclusive guaranteed supply agreement for the provision of CellPro's CEPRATE SC stem cell separation technology for gene therapy applications by Corange. The initial agreement for the development and marketing of stem cell selection products for therapeutic applications outside North America and worldwide licensing rights for diagnostic products employing the CEPRATE system will be terminated, the Seattle-based biotech firm said.
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS026150

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel